Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Serious patient-reported outcomes data gap in immunotherapy trials revealed
  • News

Serious patient-reported outcomes data gap in immunotherapy trials revealed

  • 24 November 2020
  • Janet Fricker
Serious patient-reported outcomes data gap in immunotherapy trials revealed
Total
0
Shares
0
0
0
0
0

A review of trials of immunotherapy agents revealed a ‘considerable gap’ in the use of patient reported outcomes (PROs), reports a recent study. The data analysis study found PROs were included in less than half of the 44 immunotherapy trials analysed, identifying the need for increased efforts to maximize the clinical utility of such data (Houssein S et al. J Natl Cancer Inst, 2020).

Between 2017 and 2019, the number of immunotherapies (immune checkpoint inhibitors and CAR T-cell therapies) in active development increased by 91%, from 2,020 to 3,876. PROs are self-reported questionnaires completed by patients without interpretation by clinicians, which enable patients to express their perceptions of the value of treatment regimens and the impact of a drug to be measured beyond survival benefits. Such data are considered fundamental to ensuring accurate reporting of adverse events, with several studies suggesting adverse events are best reported by patients as opposed to physicians.

The aim of the study by Jad Chahoud (Lee Moffit Cancer Center, FL) and colleagues was to provide ‘an objective review’ of the ‘strengths and limitations’ of PRO data in studies of immunotherapy agents approved by the FDA between January 2011 and December 2018. For each drug, the team identified the pivotal clinical trials used for FDA approval, and reviewed trial manuscripts (both primary and secondary) reporting PROs. To explore randomised clinical trials (RCTs), the investigators developed the 24 point PRO Endpoints Analysis Score (PROEAS) based on 24 criteria derived from recommendations of the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) Consortium. PROEAS was only applicable to RCTs, it could not be used to provide an objective scale for single-arm trials.
Overall, the investigators identified 42 immunotherapy drug approvals that had taken place between 2011 and 2018, involving 44 publications, of which 23 (52.3%) were RCTs and 21 (47.4%) single-arm trials.

The results of the systematic review showed:

  • PROs were published for 47.7% (21 out of 44) of the trial publications.
  • 11.4% of the trial publications (5 of 44) only published preliminary PRO results in the primary clinical outcomes manuscript.
  • Median time between primary clinical outcome publications and the corresponding secondary PRO publication was 19 months (IQR=9−29).
  • For the RCTs, 14 out of 23 (60.9%) published PRO data including 13 (56.5%) where it was included in a secondary dedicated manuscript.
  • Although the RCTs were published before the SISAQOL recommendations, none of the 14 RCTs publishing PRO data met the standard of all these SISAQOL recommendations, and 7 of the RCTs (half) scored <13 points on the 24-point PROEAS. The mean PROEAS score was 12.71 (range 5−17; SD=3.71).

“The fast pace at which immunotherapy is evolving comes at the cost of suboptimal reporting and delays in publishing PROs,” write the authors. “Much is still unknown about the PROs of immunotherapy drugs that have received FDA approval, as PRO data are missing for most trials. A standardized design and methodology as well as timely reporting of PROs are crucial for anticipating the real-world patient experience associated with these drugs.”

The authors comment that none of the studies used an immunotherapy-specific PRO tool, which is important since traditional PRO instruments designed for chemotherapy may fail to detect changes specific to immunotherapy drugs.

However, there is cause for optimism. At the end of the discussion the authors note that multiple new PRO tools are emerging with the potential to optimise the feasibility and usability of PROs in immunotherapy studies. Examples include the PRO-CTCAE, which provides a flexible approach across a broad range of cancer therapies; and the FACTGP5, consisting of one question addressing the extent to which patients are bothered by treatment side effects. “These tools have the potential to maximize the relevance of PRO data in clinical decision making and could offer trialists a valuable addition in the design of future immunotherapy trials,” write the authors, adding that the next step is to move to proper implementation of these tools to maximize the value of PRO data.

Bettina Ryll, founder of the Melanoma Patient Network Europe, the first condition for which checkpoint inhibitors were approved, says, “PROs are immensely valuable because they elicit information from the primary data source, the patient, thereby avoiding the biases that reporting by proxies introduces. This systematic review accurately depicts the struggles that are being experienced establishing PROs for new therapeutic classes, like checkpoint inhibitors. The problem being they behave entirely differently from previous therapies, limiting usability of existing PRO tools.” It would be desirable, she adds, if the introduction of news classes of drugs were accompanied by corresponding PRO development strategies based on high-quality qualitative work.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • Adverse events
  • immunotherapy
  • patient-reported outcomes
  • PRO tools
  • randomised clinical trials
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles

Cancer-associated thrombosis: awareness and action can save many lives

  • 21 November 2020
  • Rachel Brazil
View Post
Next Article
  • News

Prolonged ADT use in prostate cancer increases CV mortality: A need for cardiovascular protection

  • 27 November 2020
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.